Jove
Visualize
Contact Us

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MBP - Journal scope update.

Molecular and biochemical parasitology·2025
Same author

Editorial.

Molecular and biochemical parasitology·2017
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 5, 2026

Worm-align and Worm_CP, Two Open-Source Pipelines for Straightening and Quantification of Fluorescence Image Data Obtained from Caenorhabditis elegans
11:16

Worm-align and Worm_CP, Two Open-Source Pipelines for Straightening and Quantification of Fluorescence Image Data Obtained from Caenorhabditis elegans

Published on: May 28, 2020

Fighting killer worms.

Patrick Skelly1

  • 1Cummings School of Veterianary Medicine, Tufts University, USA.

Scientific American
|May 1, 2008
PubMed
Summary
This summary is machine-generated.

Schistosomiasis, a debilitating parasitic worm disease, urgently needs a vaccine due to treatment limitations and high reinfection rates. New genetic tools offer hope for developing effective schistosomiasis vaccines.

More Related Videos

A Protocol to Infect Caenorhabditis elegans with Salmonella typhimurium
06:50

A Protocol to Infect Caenorhabditis elegans with Salmonella typhimurium

Published on: June 26, 2014

Evaluation of Motor Impairment in C. elegans Models of Amyotrophic Lateral Sclerosis
08:27

Evaluation of Motor Impairment in C. elegans Models of Amyotrophic Lateral Sclerosis

Published on: September 2, 2021

Related Experiment Videos

Last Updated: Jul 5, 2026

Worm-align and Worm_CP, Two Open-Source Pipelines for Straightening and Quantification of Fluorescence Image Data Obtained from Caenorhabditis elegans
11:16

Worm-align and Worm_CP, Two Open-Source Pipelines for Straightening and Quantification of Fluorescence Image Data Obtained from Caenorhabditis elegans

Published on: May 28, 2020

A Protocol to Infect Caenorhabditis elegans with Salmonella typhimurium
06:50

A Protocol to Infect Caenorhabditis elegans with Salmonella typhimurium

Published on: June 26, 2014

Evaluation of Motor Impairment in C. elegans Models of Amyotrophic Lateral Sclerosis
08:27

Evaluation of Motor Impairment in C. elegans Models of Amyotrophic Lateral Sclerosis

Published on: September 2, 2021

Area of Science:

  • Neglected tropical diseases
  • Parasitology
  • Vaccinology

Background:

  • Schistosomiasis is a major global health problem, causing significant morbidity and mortality, particularly in sub-Saharan Africa.
  • Current treatments for schistosomiasis are insufficient to prevent widespread reinfection, highlighting the need for alternative control strategies.

Purpose of the Study:

  • To review the current challenges in schistosomiasis control.
  • To explore the potential of novel vaccine candidates for schistosomiasis prevention.

Main Methods:

  • Review of existing literature on schistosomiasis epidemiology and treatment.
  • Analysis of advancements in genetic and molecular technologies for vaccine development.

Main Results:

  • Existing treatments for schistosomiasis are hampered by high rates of reinfection.
  • No currently available vaccine has proven effective against schistosomiasis.

Conclusions:

  • Development of an effective schistosomiasis vaccine is critical to reduce disease burden.
  • Genetic and other emerging tools show promise for the creation of novel and effective schistosomiasis vaccine candidates.